Priavoid and PRInnovation have reached a significant milestone with the completion of recruitment for the clinical Phase II study of the Alzheimer's drug PRI-002.

The state needs to make savings. But we must not scrimp on the future. In this contribution, Rafael Laguna de la Vera and Thomas Ramge explain how more can be achieved with less in innovation (too).

To securing peace and ensuring Germany’s ability to defend itself and its sovereignty, SPRIND recommends establishing SPRIND.MIL – a military innovation agency that is structured similarly to SPRIND.